Product Reports Resources Pricing Login Book a demo

Ambrx

Biotech & Life Sciences · San Diego, United States · Founded 2003 · IPO 2021

A biopharmaceutical company with a mission to deliver breakthrough protein therapeutics

Valuation $1.55B
Revenue $7.4M
Power Law Unicorn$1–10B valuation tier

Investors

22 investors on Ambrx's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 1 investor entered at this stage
M Ventures
Series B+ 21 investors entered at this stage
Tavistock Group
University of California
Berkeley
BlackRock
Sinopharm Group
Adage Capital
Apricot Capital
Roche Venture Fund
Versant Ventures
China Everbright Limited
CMEA Capital
Cormorant Asset Management
5AM Ventures
Northeast Securities
Maverick Capital
Fidelity Investments
Invus
Apposite Capital
Aravis Ventures
Suvretta Capital Management
Maverick Ventures Israel

Ambrx mafia

Startups founded by Ambrx alumni

Former Ambrx employees who went on to start their own companies. Sorted by Dealroom signal score.

ArdelyxEst. 2007
PSPeter SchultzUnited States
Signal score89
TRIO PharmaceuticalsEst. 2018
SBShiva BhowmikUnited States
Signal score76
Ablaze PharmaceuticalsEst. 2021
Alan XuChina
Signal score65
Avidity BiosciencesEst. 2013
Troy WilsonUnited States
Signal score62
Effector TherapeuticsEst. 2012
Kevin EastwoodUnited States
Signal score60

Book a demo to explore the full alumni network →

Global footprint

Where Ambrx has talent and traffic

Workforce by country
2 countries with
team presence
🇺🇸 United States94%
🇨🇳 China3%
2 countries shown
Web traffic by country
1.7K monthly visits
across markets
🇺🇸 United States41.2%
🇹🇷 Turkey29.4%
🇮🇳 India29.4%
Top 3 markets shown

Talent graph

The shape of Ambrx's talent

Dealroom maps Ambrx's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

DimensionScore
AI Talent Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Ambrx's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$127M patent portfolio · 43 active families

Estimated portfolio value
$127M
8.2% of market cap · 7.2× larger than top peer Vaxcyte ($17M)
43 active patent families
Where Ambrx innovates Amino acidAntiendomysial antibodiesBiochemistryBiological organismCell biology

Where Ambrx concentrates vs peers

Each axis is a top-10 topic across Ambrx and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Ambrx

An AI-synthesized read of the highest-engagement posts about Ambrx on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Ambrx on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles